JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of JNJ-64281802 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-64281802

First Posted Date: 2022-01-21

Last Posted Date: 2023-04-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 33

Registration Number: NCT05201937

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Phase 4

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Cilta-cel

First Posted Date: 2022-01-21

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 228

Registration Number: NCT05201781

Locations: 🇨🇳
First Hospital, Zhejiang University Medical College, Hangzhou, China
🇨🇳
Jiangsu Province Hospital, Nanjing, China
🇨🇳
Ruijin Hospital Shanghai Jiao Tong University, Shanghai, China

and more 43 locations

A Study of JNJ-64281802 for the Prevention of Dengue Infection

Phase 2

Terminated

Conditions: Dengue

Interventions: Drug: JNJ-64281802
Drug: Placebo

First Posted Date: 2022-01-21

Last Posted Date: 2025-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 1256

Registration Number: NCT05201794

Locations: 🇧🇷
Centro Bangu - Centro Municipal de Saude Waldyr Franco, Rio de Janeiro, Brazil
🇧🇷
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base, Sao Jose do Rio Preto, Brazil
🇧🇷
Universidade Federal De Minas Gerais - Hospital das Clínicas, Belo Horizonte, Brazil

and more 35 locations

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

Phase 3

Active, not recruiting

Conditions: Crohn Disease

Interventions: Drug: Guselkumab Dose 1
Drug: Placebo
Drug: Guselkumab Dose 2
Drug: Guselkumab Dose 3

First Posted Date: 2022-01-19

Last Posted Date: 2024-10-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 350

Registration Number: NCT05197049

Locations: 🇧🇷
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base, Sao Jose do Rio Preto, Brazil
🇺🇸
Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
🇺🇸
Advanced Gastro P.C, Chandler, Arizona, United States

and more 337 locations

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

Phase 1

Completed

Conditions: Human Immunodeficiency Virus (HIV)

Interventions: Drug: DRV/COBI FDC

First Posted Date: 2022-01-19

Last Posted Date: 2023-09-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 15

Registration Number: NCT05197075

Locations: 🇪🇸
Hosp. Gral. Univ. Gregorio Maranon, Madrid, Spain
🇿🇦
Global Clinical Trials PE, Pretoria, South Africa
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 3 locations

A Study of 14C JNJ-67953964 in Healthy Adult Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 14C-aticaprant

First Posted Date: 2022-01-19

Last Posted Date: 2022-04-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 8

Registration Number: NCT05197062

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy

Completed

Conditions: Pigmentary Retinopathy
Pigmentary Maculopathy
Interstitial Cystitis

First Posted Date: 2022-01-05

Last Posted Date: 2023-12-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 2

Registration Number: NCT05179460

Locations: 🇺🇸
Janssen R&D, LLC, Titusville, New Jersey, United States

Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)

Conditions: Multiple Myeloma

First Posted Date: 2021-12-17

Last Posted Date: 2024-12-24

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT05161598

A Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on Rilematovir

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rilematovir
Drug: Ciclosporin

First Posted Date: 2021-12-13

Last Posted Date: 2022-02-17

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 18

Registration Number: NCT05155007

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study of JNJ-80202135 in Healthy Chinese Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Nipocalimab

First Posted Date: 2021-12-09

Last Posted Date: 2022-10-26

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 30

Registration Number: NCT05151692

Locations: 🇨🇳
Peking University Third Hospital, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy